Drug intelligence / Profile preview

Katiwin

Development stage: Unknown
Lead developer: SKM Siddha and Ayurveda Company
Administration: Oral

Overview

Katiwin is a proprietary traditional herbal formulation developed by SKM Siddha and Ayurveda Company, officially launched in 2024. It is a Siddha-based medicinal product specifically indicated for the management of musculoskeletal conditions affecting the lower back, such as Kati Shoola (lower back pain) and lumbar spondylosis. The formulation utilizes a blend of traditional herbs known in Siddha medicine for their anti-inflammatory and analgesic properties to alleviate spinal discomfort and improve mobility in the lumbar region. As a traditional ASU (Ayurveda, Siddha, and Unani) drug, it is marketed as a completed product rather than an investigational candidate undergoing conventional clinical trial phases.

Brand names: Katiwin

Beyond the preview

Go deeper on Katiwin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Katiwin.

Explore the full profile